$PHAT

Phathom Pharmaceuticals (PHAT) faces a lawsuit from BDR challenging FDA's refusal to grant an ANDA for VOQUEZNA and the application of the GAIN Act, which extends exclusivity until 2032. The company plans to defend its exclusivity rights. The outcome may significantly impact VOQUEZNA's market position.

Jefferies reduced its price target for Phathom Pharmaceuticals (NASDAQ:PHAT) to $16 from $20, citing a challenging year but a favorable 2027 outlook. The stock has fallen 58% year-to-date. Phathom reported Q2 2026 revenue of $74.27 million, up 88% YoY, but adjusted its full-year revenue guidance downward due to logistical issues. Analysts remain bullish, with H.C. Wainwright and Guggenheim maintaining Buy ratings.

Phathom Pharmaceuticals presented data at ACG 2026 showing VOQUEZNA® (vonoprazan) is cost-effective vs. PPIs for Erosive GERD, with potential savings. Additional studies showed efficacy across BMI subgroups and severe GERD profiles. 38 independent abstracts on vonoprazan were also presented, reflecting broad clinical interest. According to the company, the drug may offer economic value and healthcare savings over time.

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 29, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • ~1.7 million total VOQUEZNA ® prescriptions filled to date • Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 • Q2 operatin

Phathom Pharmaceuticals (PHAT) released its Q1 2026 results, reporting $57.6 million in revenue and a significant reduction in EPS loss to $0.29. The company's net losses have shrunk from $94.3 million to $21.1 million over six quarters, supporting a bullish outlook on its path to profitability within three years. Despite ongoing trailing losses and negative shareholders' equity, analysts maintain a high fair value and price target, fueled by strong revenue growth forecasts and expected margin improvements.

Phathom Pharmaceuticals (PHAT) reported Q4 2025 revenue of US$57.6 million and a narrowed basic EPS loss of US$0.29, with a net loss of US$21.1 million. While revenue growth is strong, trailing 12-month net losses remain substantial at US$221.25 million, raising questions about the company's path to profitability and challenging the bullish narrative that anticipates 25.4% margins within three years. Despite the narrowing quarterly losses, the overall financial health, including negative shareholders' equity, indicates that profitability is still a significant work in progress.

Raymond James analysts are highlighting two "Strong Buy" stocks, Lexeo Therapeutics (LXEO) and Phathom Pharmaceuticals (PHAT), for 2026, anticipating strong performance in the coming year. Lexeo, developing gene therapies for inherited cardiovascular diseases and Alzheimer's, is backed by advancing clinical data and regulatory momentum, with significant revenue projections for its lead asset. Phathom Pharmaceuticals, which focuses on acid-related GI issues, shows promising revenue growth for its approved drug Voquezna, combined with improving cost discipline and new leadership, signaling an attractive long-term risk/reward scenario.

FLORHAM PARK, N.J., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of its management team are scheduled ...

Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170-$175 million.